Novel treatment strategies for schizophrenia from improved understanding of genetic risk

Clinical Genetics

Volumn 86, Issue 5, 2014, Pages 401-411

  Morris, B J ^a,b   Pratt, J A ^a,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

CNV; Disc1 interactome; Drug discovery; Genome; GWAS; Kinase; Rac; Schizophrenia; Signalling

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CALCIUM CHANNEL; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EXCITATORY AMINO ACID TRANSPORTER 3; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATASE; LOW DENSITY LIPOPROTEIN RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUREXIN; PHOSPHODIESTERASE; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN CDC42; PROTEIN P21; RAC PROTEIN; RAC1 PROTEIN; RHO FACTOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; CELL SURFACE RECEPTOR; ION CHANNEL;

COPY NUMBER VARIATION; GENE DUPLICATION; GENE FUNCTION; GENE LOCUS; GENETIC RISK; GENOME-WIDE ASSOCIATION STUDY; GLUTAMATERGIC SYNAPSE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; POSTSYNAPTIC POTENTIAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT PLANNING; GENETIC PREDISPOSITION; GENETICS; METABOLISM; RISK FACTOR; TRANSLATIONAL RESEARCH;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; ION CHANNELS; RECEPTORS, CELL SURFACE; RISK FACTORS; SCHIZOPHRENIA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84911983641     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12485     Document Type: Review

References (69)

1. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "Just the Facts": what we know in 2008: part 1: overview. Schizophr Res 2008: 100: 4-19.
2. Millar JK, Wilson-Annan JC, Anderson S et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000: 9: 1415-1423.
3. Doherty JL, O'Donovan MC, Owen MJ. Recent genomic advances in schizophrenia. Clin Genet 2012: 81: 103-109.
4. Fromer M, Pocklington AJ, Kavanagh DH et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014: 506: 179-184.
5. Kirov G, Rees E, Walters JTR et al. The penetrance of copy number variations for schizophrenia and developmental delay. Biol Psychiatry 2014: 75: 378-385.
6. Owen MJ. Implications of genetic findings for understanding schizophrenia. Schizophr Bull 2012: 38: 904-907.
7. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 2005: 5: 1-6.
8. Pratt JA, Winchester CW, Egerton A, Cochran SA, Morris BJ. Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br J Pharmacol 2008: 153: S465-S470.
9. Glessner JT, Reilly MP, Kim CE et al. Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci USA 2010: 107: 10584-10589.
10. Kirov G, Pocklington AJ, Holmans P et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 2012: 17: 142-153.
11. Purcell SM, Moran JL, Fromer M et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014: 506: 185-190.
12. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014: 511: 421-427.
13. Winchester CL, Pratt JA, Morris BJ. Risk genes for schizophrenia: translational opportunities for drug discovery. Pharmacol Ther 2014: 143: 34-50.
14. Coffey ET. Nuclear and cytosolic JNK signalling in neurons. Nat Rev Neurosci 2014: 15: 285-299.
15. Pickard BS, Malloy MP, Christoforou A et al. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry 2006: 11: 847-857.
16. Carroll LS, Williams HJ, Walters J, Kirov G, O'Donovan MC, Owen MJ. Mutation screening of the 3q29 microdeletion syndrome candidate genes DLG1 and PAK2 in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2011: 156B: 844-849.
17. Mulle JG, Dodd AF, McGrath JA et al. Microdeletions of 3q29 confer high risk for schizophrenia. Am J Hum Genet 2010: 87: 229-236.
18. Walsh T, McClellan JM, McCarthy SE et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008: 320: 539-543.
19. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 2010: 11: 100-113.
20. Vinkers CH, Mirza NR, Olivier B et al. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. Expert Opin Investig Drugs 2010: 19: 1217-1233.
21. Buizer-Voskamp JE, Muntjewerff JW, Strengman E et al. Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients. Biol Psychiatry 2011: 70: 655-662.
22. Freedman R. Alpha7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med 2014: 65: 245-261.
23. Green EK, Grozeva D, Jones I et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry 2010: 15: 1016-1022.
24. Ripke S, Consortium SPG-WASG. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011: 43: 969-976.
25. Ripke S, O'Dushlaine C, Chambert K et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013: 45: 1150-1159.
26. Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007: 13: 1102-1107.
27. Adams D, Kinon B, Baygani S et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry 2013: 13: 143.
28. Timms AE, Dorschner MO, Wechsler J et al. Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 2013: 70: 582-590.
29. Levinson DF, Duan J, Oh S et al. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry 2011: 168: 302-316.
30. Vacic V, McCarthy S, Malhotra D et al. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 2011: 471: 499-503.
31. Rees E, Walters JTR, Georgieva L et al. Analysis of copy number variations at 15 schizophrenia-associated loci. Br J Psychiatry 2014: 204: 108-114.
32. Hu X, Zhang B, Liu W et al. A survey of rare coding variants in candidate genes in schizophrenia by deep sequencing. Mol Psychiatry 2013: 19: 858-859.
33. Girard SL, Gauthier J, Noreau A et al. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet 2011: 43: 860-863.
34. Need Anna C, McEvoy Joseph P, Gennarelli M et al. Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. Am J Hum Genet 2012: 91: 303-312.
35. Shi J, Levinson DF, Duan J et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009: 460: 753-757.
36. Costain G, Lionel AC, Fu F et al. Adult neuropsychiatric expression and familial segregation of 2q13 duplications. Am J Med Genet B Neuropsychiatr Genet 2014: 165: 337-344.
37. Rees E, Walters JT, Chambert KD et al. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Hum Mol Genet 2014: 23: 1669-1676.
38. Myles-Worsley M, Tiobech J, Browning SR et al. Deletion at the SLC1A1 glutamate transporter gene co-segregates with schizophrenia and bipolar schizoaffective disorder in a 5-generation family. Am J Med Genet B Neuropsychiatr Genet 2013: 162: 87-95.
39. Millar JK, Pickard BS, Mackie S et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 2005: 310: 1187-1191.
40. O'Kane EM, Stone TW, Morris BJ. Distribution of Rho family GTPases in the adult rat hippocampus and cerebellum. Mol Brain Res 2003: 114: 1-8.
41. O'Kane EM, Stone TW, Morris BJ. Activation of Rho GTPases by synaptic transmission in the hippocampus. J Neurochem 2003: 87: 1309-1312.
42. Camargo LM, Collura V, Rain J-C et al. Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry 2006: 12: 74-86.
43. Zhao Q, Li T, Zhao X et al. Rare CNVs and tag SNPs at 15q11.2 are associated with schizophrenia in the Han Chinese population. Schizophr Bull 2013: 39: 712-719.
44. Xu B, Ionita-Laza I, Roos JL et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet 2012: 44: 1365-1369.
45. Xu B, Woodroffe A, Rodriguez-Murillo L et al. Elucidating the genetic architecture of familial schizophrenia using rare copy number variant and linkage scans. Proc Natl Acad Sci U S A 2009: 106: 16746-16751.
46. Need AC, Ge D, Weale ME et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet 2009: 5: e1000373.
47. Wong EH, So HC, Li M et al. Common variants on Xq28 conferring risk of schizophrenia in Han Chinese. Schizophr Bull 2013: 40: 777-786.
48. Ohi K, Hashimoto R, Nakazawa T et al. The p250GAP gene is associated with risk for schizophrenia and schizotypal personality traits. PLoS One 2012: 7: e35696.
49. Hayashi-Takagi A, Araki Y, Nakamura M et al. PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc Natl Acad Sci USA 2014: 111: 6461-6466.
50. Wang Q, Charych EI, Pulito VL et al. The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function. Mol Psychiatry 2011: 16: 1006-1023.
51. Hussain NK, Hsin H, Huganir RL, Sheng M. MINK and TNIK differentially act on Rap2-mediated signal transduction to regulate neuronal structure and AMPA receptor function. J Neurosci 2010: 30: 14786-14794.
52. Coba MP, Komiyama NH, Nithianantharajah J et al. TNiK is required for postsynaptic and nuclear signaling pathways and cognitive function. J Neurosci 2012: 32: 13987-13999.
53. Potkin SG, Turner JA, Fallon JA et al. Gene discovery through imaging genetics: identification of two novel genes associated with schizophrenia. Mol Psychiatry 2008: 14: 416-428.
54. Zheng X, Bei J-X, Xu H et al. The association between rare large duplication of 16p11.2 and schizophrenia in the Singaporean Chinese population. Schizophr Res 2013: 146: 368-369.
55. McCarthy SE, Makarov V, Kirov G et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009: 41: 1223-1227.
56. Addington AM, Rapoport JL. The genetics of childhood-onset schizophrenia: when madness strikes the prepubescent. Curr Psychiatry Rep 2009: 11: 156-161.
57. Steinberg S, de Jong S, Mattheisen M et al. Common variant at 16p11.2 conferring risk of psychosis. Mol Psychiatry 2012: 19: 108-114.
58. Van Den Bossche MJ, Strazisar M, Cammaerts S et al. Identification of rare copy number variants in high burden schizophrenia families. Am J Med Genet B Neuropsychiatr Genet 2013: 162: 273-282.
59. Stefansson H, Rujescu D, Cichon S et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008: 455: 232-236.
60. Li M, Wang Y, Zheng X-b et al. Meta-analysis and brain imaging data support the involvement of VRK2 (rs2312147) in schizophrenia susceptibility. Schizophr Res 2012: 142: 200-205.
61. Steinberg S, de Jong S, Andreassen OA et al. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet 2011: 20: 4076-4081.
62. Winchester CL, Ohzeki H, Vouyiouklis DA et al. Converging evidence that sequence variations in the novel candidate gene MAP2K7 (MKK7) are functionally associated with schizophrenia. Hum Mol Genet 2012: 21: 4910-4921.
63. Bassett AS, Costain G, Alan Fung WL et al. Clinically detectable copy number variations in a Canadian catchment population of schizophrenia. J Psychiatr Res 2010: 44: 1005-1009.
64. Yamasaki T, Kawasaki H, Arakawa S et al. Stress-activated protein kinase MKK7 regulates axon elongation in the developing cerebral cortex. J Neurosci 2011: 31: 16872-16883.
65. Fuller G, Veitch K, Lai Kwan H, Cruise L, Morris BJ. Activation of p44/p42 MAP kinase in striatal neurons via kainate receptors and PI3 kinase. Mol Brain Res 2001: 89: 126-132.
66. Clark CJ, McDade DM, O'Shaughnessy CT, Morris BJ. Contrasting roles of neuronal Msk1 and Rsk2 in Bad phosphorylation and feedback regulation of Erk signalling. J Neurochem 2007: 102: 1024-1034.
67. Pratt JA, Winchester C, Dawson N, Morris BJ. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov 2012: 11: 560-579.
68. Costain G, Lionel AC, Fu F et al. Adult neuropsychiatric expression and familial segregation of 2q13 duplications. Am J Med Genet B Neuropsychiatr Genet 2014: 165(B): 337-344.
69. Mulle JG, Pulver AE, McGrath JA et al. Reciprocal duplication of the Williams-Beuren syndrome deletion on chromosome 7q11.23 is associated with schizophrenia. Biol Psychiatry 2014: 75: 371-377.